AstraZeneca expands obesity push as it invests $125M in ultrasound medicine

Key Takeaways

• VISTA (n=310): elecoglipron 75 mg cut mean body weight 10.5% at 26 weeks vs 0.6% placebo; 11.8% at 36 weeks vs 0.3% placebo.
• SOLSTICE (n=404): elecoglipron 75 mg lowered mean HbA1c 1.9% at 26 weeks vs 0.2% placebo; 90% reached HbA1c <7%.
• Safety was described as consistent with the GLP-1 class; GI events predominated and were mostly mild to moderate.
• Phase 3 includes EMBOLD (obesity/overweight) and ELUMINATE (type 2 diabetes ± dapagliflozin), plus CV and kidney outcome trials.

What changed in AstraZeneca’s obesity and diabetes push?

AstraZeneca said positive Phase 2b results for once-daily oral elecoglipron support moving into an extensive Phase 3 programme across obesity and type 2 diabetes. Results were presented at the ADA 2026 Scientific Sessions and published simultaneously in The Lancet.

Partner Eccogene also highlighted ADA presentations covering China Phase 1b and the global VISTA/SOLSTICE programme in a June 2026 Business Wire release.

What efficacy numbers did VISTA and SOLSTICE report?

In VISTA, adults with obesity or overweight plus at least one comorbidity on elecoglipron 75 mg achieved a statistically significant average weight reduction of 10.5% at 26 weeks versus 0.6% with placebo; weight loss reached 11.8% at 36 weeks versus 0.3% with placebo. Up to 88.8% of participants on elecoglipron achieved at least 5% weight loss at 26 weeks.

In SOLSTICE, adults with type 2 diabetes on elecoglipron 75 mg achieved a 1.9% average HbA1c reduction at 26 weeks versus 0.2% with placebo. About 90% reached HbA1c below 7%, and 85% reached 6.5% or lower. Mean weight fell 7.7% versus 1.7% with placebo. Peer-reviewed context is available via The Lancet SOLSTICE abstract.

• VISTA enrollment: 310 participants
• SOLSTICE enrollment: 404 participants
• Oral once-daily dosing with no food or fluid restrictions described for elecoglipron

How is the Phase 3 programme structured?

EMBOLD Phase 3 trials will evaluate elecoglipron in people with obesity or overweight, with and without type 2 diabetes. ELUMINATE Phase 3 trials will evaluate elecoglipron as monotherapy and with dapagliflozin in type 2 diabetes. Additional outcome trials will focus on long-term cardiovascular and kidney endpoints.

Related early clinical listings include NCT06579092 (VISTA) and NCT06579105 (SOLSTICE) on ClinicalTrials.gov.

What factual correction matters for this news cycle?

A same-week industry roundup also covered a separate $125 million Series B for SonoThera’s ultrasound-mediated genetic medicines platform. That financing is not an AstraZeneca investment in ultrasound medicine. This article therefore centers on AstraZeneca’s sourced elecoglipron Phase 3 decision and does not attribute the $125 million raise to AstraZeneca.

What remains unproven?

Phase 2b efficacy estimand results do not establish Phase 3 success, cardiovascular outcomes, kidney outcomes, or comparative superiority versus other oral GLP-1 agents. Discontinuation rates, long-term tolerability after revised dose-escalation schedules, and commercial dosing strategy remain open until Phase 3 reads out.

Related NovaPharma coverage

• Merck and Gilead report mixed outcomes in lung cancer and HIV studies
• KEYTRUDA (pembrolizumab) profile
• FDA Drug Approval: What Approval Means for Pharma Marketing and BD

Frequently Asked Questions

Primary Sources

1. Business Wire: elecoglipron ADA 2026 data
2. The Lancet: SOLSTICE Phase 2b abstract
3. ClinicalTrials.gov NCT06579092 (VISTA)